Prevention of cardiotoxicity among survivors of childhood cancer

• Published in: British journal of clinical pharmacology Vol. 83; no. 3; pp. 455 - 465
• Main Authors: Hutchins, Kelley K., Siddeek, Hani, Franco, Vivian I., Lipshultz, Steven E.
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01-03-2017
• Subjects: Anthracyclines - adverse effects; Antibiotics, Antineoplastic - adverse effects; Cancer Survivors; Cardiotonic Agents - therapeutic use; cardiotoxicity; Cardiotoxicity - prevention & control; childhood cancer; dexrazoxane; Dexrazoxane - therapeutic use; Humans; Models, Cardiovascular; Review; survivor; cardiotoxicity; dexrazoxane; childhood cancer; survivor
• ISSN: 0306-5251; 1365-2125; 1365-2125
• DOI: 10.1111/bcp.13120

Linked Articles
This article is part of a joint Themed section with the British Journal of Pharmacology on Cardiotoxicity. The rest of the Themed section will appear in a future issue of BJP and will be available at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476‐5381
The number of survivors of childhood cancers has increased exponentially over the past few decades. However, these survivors are also at substantially increased long‐term risk of morbidity and mortality, especially from treatment‐related cardiotoxicity. Preventing these risks is now a priority when treating children and adolescents with cancer. Dexrazoxane reduces the risk of anthracycline‐induced cardiotoxicity among adults and children with cancer without reducing its antineoplastic effects or event‐free survival. Thus, it should be strongly considered as a part of therapy for children and adolescents treated with anthracyclines.